Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

There is a great need for efficacious therapies against Gram-negative bacteria. Double β-lactam combination(s) (DBL) are relatively safe, and preclinical data are promising; however, their clinical role has not been well defined. We conducted a metaanalysis of the clinical and microbiological effica...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Jiao, Yuanyuan, Moya, Bartolome, Chen, Mong-Jen, Zavascki, Alexandre P., Tsai, Hsinyin, Tao, Xun, Sutaria, Dhruvitkumar S., Louie, Arnold, Boyce, John D., Deveson Lucas, Deanna, Kim, Tae Hwan, Tsuji, Brian T., Bonomo, Robert A., Drusano, George L., Bulitta, Jürgen B.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2019
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591590/
https://ncbi.nlm.nih.gov/pubmed/30988147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00425-19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires